StreetInsider.com News Articles

Johnson & Johnson invests $1 billion in Jacksonville vision manufacturing

Mon, 15 Jun 2026 06:01:23 -0400

Johnson & Johnson (NYSE: JNJ) announced an investment of more than $1 billion in its Jacksonville, Florida operations to expand Vision manufacturing, packaging and distribution capabilities.

The investment includes construction of a new distribution facility and advanced manufacturing technologies to increase capacity for ACUVUE contact lenses. The company manufactures more than 1.7 billion ACUVUE contact lenses annually for U.S. patients, serving more than 40 million patients globally.

Construction is underway with the goal of full operation by 2028. The investment supports 3,500 Jacksonville employees and is part of Johnson & Johnson's previously announced $55 billion U.S. investment in manufacturing, research and development,

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

Mon, 15 Jun 2026 06:00:00 -0400

Investment includes new advanced manufacturing and packaging technologies and a new state-of-the-art distribution facility to scale the Company’s U.S. Vision operations, enhance supply chain resilience, and meet the needs of more than 40 million patients
Investment is part of the Company’s ongoing $55 billion commitment to U.S. manufacturing, research and development, and technology through early 2029
Building on more than 40 years of leadership in Florida, the investment supports 3,500 Jacksonville employees and strengthens Johnson & Johnson’s $6 billion annual economic impact across the state

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

Mon, 15 Jun 2026 06:00:00 -0400

Investment includes new advanced manufacturing and packaging technologies and a new state-of-the-art distribution facility to scale the Company’s U.S. Vision operations, enhance supply chain resilience, and meet the needs of more than 40 million patients
Investment is part of the Company’s ongoing $55 billion commitment to U.S. manufacturing, research and development, and technology through early 2029
Building on more than 40 years of leadership in Florida, the investment supports 3,500 Jacksonville employees and strengthens Johnson & Johnson’s $6 billion annual economic impact across the state

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

Mon, 15 Jun 2026 06:00:00 -0400

Investment includes new advanced manufacturing and packaging technologies and a new state-of-the-art distribution facility to scale the Company’s U.S. Vision operations, enhance supply chain resilience, and meet the needs of more than 40 million patients
Investment is part of the Company’s ongoing $55 billion commitment to U.S. manufacturing, research and development, and technology through early 2029
Building on more than 40 years of leadership in Florida, the investment supports 3,500 Jacksonville employees and strengthens Johnson & Johnson’s $6 billion annual economic impact across the state

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

Mon, 15 Jun 2026 06:00:00 -0400

Investment includes new advanced manufacturing and packaging technologies and a new state-of-the-art distribution facility to scale the Company’s U.S. Vision operations, enhance supply chain resilience, and meet the needs of more than 40 million patients
Investment is part of the Company’s ongoing $55 billion commitment to U.S. manufacturing, research and development, and technology through early 2029
Building on more than 40 years of leadership in Florida, the investment supports 3,500 Jacksonville employees and strengthens Johnson & Johnson’s $6 billion annual economic impact across the state

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

Mon, 15 Jun 2026 06:00:00 -0400

Investment includes new advanced manufacturing and packaging technologies and a new state-of-the-art distribution facility to scale the Company’s U.S. Vision operations, enhance supply chain resilience, and meet the needs of more than 40 million patients
Investment is part of the Company’s ongoing $55 billion commitment to U.S. manufacturing, research and development, and technology through early 2029
Building on more than 40 years of leadership in Florida, the investment supports 3,500 Jacksonville employees and strengthens Johnson & Johnson’s $6 billion annual economic impact across the state

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

Mon, 15 Jun 2026 06:00:00 -0400

Investment includes new advanced manufacturing and packaging technologies and a new state-of-the-art distribution facility to scale the Company’s U.S. Vision operations, enhance supply chain resilience, and meet the needs of more than 40 million patients
Investment is part of the Company’s ongoing $55 billion commitment to U.S. manufacturing, research and development, and technology through early 2029
Building on more than 40 years of leadership in Florida, the investment supports 3,500 Jacksonville employees and strengthens Johnson & Johnson’s $6 billion annual economic impact across the state

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

Mon, 15 Jun 2026 06:00:00 -0400

Investment includes new advanced manufacturing and packaging technologies and a new state-of-the-art distribution facility to scale the Company’s U.S. Vision operations, enhance supply chain resilience, and meet the needs of more than 40 million patients
Investment is part of the Company’s ongoing $55 billion commitment to U.S. manufacturing, research and development, and technology through early 2029
Building on more than 40 years of leadership in Florida, the investment supports 3,500 Jacksonville employees and strengthens Johnson & Johnson’s $6 billion annual economic impact across the state

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

Mon, 15 Jun 2026 06:00:00 -0400

Investment includes new advanced manufacturing and packaging technologies and a new state-of-the-art distribution facility to scale the Company’s U.S. Vision operations, enhance supply chain resilience, and meet the needs of more than 40 million patients
Investment is part of the Company’s ongoing $55 billion commitment to U.S. manufacturing, research and development, and technology through early 2029
Building on more than 40 years of leadership in Florida, the investment supports 3,500 Jacksonville employees and strengthens Johnson & Johnson’s $6 billion annual economic impact across the state

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most

Johnson & Johnson shows positive results for TALVEY-DARZALEX drug combination

Sun, 14 Jun 2026 14:01:12 -0400

Johnson & Johnson (NYSE: JNJ) announced results from its Phase 3 MonumenTAL-3 study showing that TALVEY (talquetamab-tgvs) combined with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) with or without pomalidomide demonstrated a significant reduction in disease progression risk compared to standard treatment in patients with relapsed or refractory multiple myeloma.

The study showed progression-free survival rates of up to 81.3% and overall survival rates of up to 89.2% at 24 months for the combination treatments, compared to 51.2% and 79.1% respectively for the standard care regimen. The combination reduced the risk of disease progression or death by up to 72% and the risk

Johnson & Johnson shows positive results for TALVEY-DARZALEX drug combination

Sun, 14 Jun 2026 14:01:12 -0400

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple my